ReviewMolecules (Basel, Switzerland)2023
Targeting mTOR for Anti-Aging and Anti-Cancer Therapy.
Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- RNF214 silencing attenuates prostate cancer progression and modulates mTOR signaling through CAV1 ubiquitination.Cell & bioscience · 2026Article
- Fluphenazine, an antipsychotic compound, ameliorates Alzheimer's disease by clearing amyloid beta accumulation in C. elegans.GeroScience · 2026Article
- Dietary Polyphenols in Brain Aging: Molecular Mechanisms and Implications for Neurodegeneration.Nutrients · 2026Review
- Article
- Article
- Computational Simulation of the Bioactivity of Selected Compounds Derived From the Sapium and Salvias Genera as Anticancer Agents.BioMed research international · 2026Article
- Targeting the AKT/mTOR axis: pectolinarigenin induces autophagy and apoptosis in human cervical cancer cells.Frontiers in pharmacology · 2026Article
- Advances in the basic function of the small GTPase SAR1B and its regulatory role in the biological behavior of tumor cells (Review).Molecular and clinical oncology · 2026Review
- Serine metabolism reprogramming in cancer: a multi-tiered regulatory framework.Acta biochimica et biophysica Sinica · 2025Review
- Exploring the antitumor potential of cucurbitacin B in hepatocellular carcinoma through network pharmacology, molecular docking, and molecular dynamics simulations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Wuhu decoction regulates ROS/AMPK/mTOR pathway-mediated dendritic cells autophagy and pyroptosis for the treatment of respiratory syncytial virus-induced asthma.Journal of thoracic disease · 2025Article
- Rewinding the Clock: Emerging Pharmacological Strategies for Human Anti-Aging Therapy.International journal of molecular sciences · 2025Review
- Relationship of Ageing to Insulin Resistance and Atherosclerosis.Metabolites · 2025Review
- Advancements in the investigation of the mechanisms underlying cognitive aging.Biogerontology · 2025Review
- Combination of rapamycin and adipose-derived mesenchymal stromal cells enhances therapeutic potential for osteoarthritis.Stem cell research & therapy · 2025Article
- Article
- Network Pharmacology, Molecular Docking, and Experimental Validation of the Mechanism of Jeduxiaoliu Formula against Diffuse Large B-Cell Lymphoma.Combinatorial chemistry & high throughput screening · 2025Article
- Cellular senescence in age-related cardiovascular disease: past and future.Frontiers in aging · 2025Review
- Autophagy-dependent apoptosis induction by oridonin are mediated by ROS-dependent AMPK-mTOR-ULK1 pathway in colon cancer.American journal of cancer research · 2025Article
- TORC1 Regulates Thermotolerance via Modulating Metabolic Rate and Antioxidant Capacity in ScallopAntioxidants (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The balance between anabolism and catabolism is disrupted with aging, with the rate of anabolism being faster than that of catabolism. Therefore, mTOR, whose major function is to enhance anabolism and inhibit catabolism, has become a potential target of inhibition for anti-aging therapy. Interestingly, it was found that the downregulation of the mTOR signaling pathway had a lifespan-extending effect resembling calorie restriction. In addition, the mTOR signaling pathway promotes cell proliferation and has been regarded as a potential anti-cancer target. Rapamycin and rapalogs, such as everolimus, have proven to be effective in preventing certain tumor growth. Here, we reviewed the basic knowledge of mTOR signaling, including both mTORC1 and mTORC2. Then, for anti-aging, we cited a lot of evidence to discuss the role of targeting mTOR and its anti-aging mechanism. For cancer therapy, we also discussed the role of mTOR signaling in different types of cancers, including idiopathic pulmonary fibrosis, tumor immunity, etc. In short, we discussed the research progress and both the advantages and disadvantages of targeting mTOR in anti-aging and anti-cancer therapy. Hopefully, this review may promote more ideas to be generated for developing inhibitors of mTOR signaling to fight cancer and extend lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.